Quotient Sciences Quotient Sciences

X
[{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Moderna Therapeutics"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces Positive Preliminary, Preclinical Data","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Hoth Therapeutics"},{"orgOrder":0,"company":"Enzo Biochem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzo Biochem Reports Publication of Study Detailing Promising Activity of Drug Candidate SK1?I in a Model of Lupus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Enzo Biochem"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Biotechnology Value Fund","pharmaFlowCategory":"D","amount":"$102.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kymera Therapeutics Announces $102 Million Series C Financing\n","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kymera Therapeutics"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis, Incyte to test Jakavi for coronavirus-linked cytokine storm","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Incyte Corporation"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Advances Cell Line Development for IMP761","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"},{"orgOrder":0,"company":"ProThera Biologics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProThera Biologics and Takeda Enter Licensing Agreement to Develop Novel Plasma-Derived Therapy Based on Inter-alpha Inhibitor Proteins","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"ProThera Biologics"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces Top Line Preclinical Data from Cutaneous Lupus Erythematosus (CLE) Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Hoth Therapeutics"},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"twoXAR Pharmaceuticals Presents Preclinical Data Demonstrating Positive Safety and Tolerability of Two Novel Lupus Drug Leads","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"twoXAR Pharmaceutical"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces Publication of Preclinical Study of EC-18 in Gouty Arthritis in Frontiers in Immunology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Enzychem Lifesciences Corporation"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Commonwealth of Pennsylvania","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Noveome Biotherapeutics Receives $4 Million Grant From Commonwealth of Pennsylvania","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Noveome Biotherapeutics"},{"orgOrder":0,"company":"Singota Solutions","sponsor":"Noveome Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Singota Solutions Collaborates with Noveome Biotherapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Singota Solutions"},{"orgOrder":0,"company":"CytoAgents","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"CytoAgents Receives NIH Funding to Accelerate Treatment for Cytokine Storm","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"CytoAgents"},{"orgOrder":0,"company":"Rallybio","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rallybio Scores $145M, Unveils Lead Rare Disease Program","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Rallybio"},{"orgOrder":0,"company":"Cellect Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cellect Biotechnology's ApoGraft\u2122 to Empower Cellular Treatment of COVID-19 Related Pulmonary Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cellect Biotechnology"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Massachusetts General Hospital"},{"orgOrder":0,"company":"Theraly Fibrosis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theraly Fibrosis Granted US Orphan Drug Designation for TLY012 for Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Theraly Fibrosis"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Further Broadens Drug Development Capabilities with Addition of R\u00f3is\u00edn Armstrong, PhD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Rallybio"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Columbus Venture\nPartners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Artax Biopharma Announces Series B Financing Extension to Advance First-in-Class Autoimmune Disease Therapy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Artax Biopharma"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Presents Preclinical Data on Novel Dual BAFF\/APRIL Inhibitory Domains for B cell Mediated Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alpine Immune Sciences"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2020 Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"VBL Therapeutics"},{"orgOrder":0,"company":"3P Biopharmaceuticals","sponsor":"Toleranzia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"3P Bio and Toleranzia Enter Orphan Drug Partnership","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"3P Biopharmaceuticals"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artax Biopharma Announces the Formation of Scientific Advisory Board to Advance Autoimmune Disease Therapy AX-158","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Artax Biopharma"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Receives Orphan Drug Designation for Tacrolimus Inhalation Powder","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"TFF Pharmaceuticals"},{"orgOrder":0,"company":"Melior Discovery","sponsor":"SFA Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melior Discovery Announces Partnership with SFA on Grant Directed to COVID-19","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Melior Discovery"},{"orgOrder":0,"company":"ILIAS Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILIAS Biologics Granted Key Patent for Exosome-based Drug Delivery System in the United States","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"ILIAS Biologics"},{"orgOrder":0,"company":"Citryll","sponsor":"BOM Brabant Ventures","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Citryll Completes \u20ac 18.5 M Fundraise to Develop CIT-013, an Antibody Targeting Neutrophil Extracellular Traps","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Citryll"},{"orgOrder":0,"company":"Sareum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Encouraging Preclinical Results Generated with Sareum\u2019s TYK2\/JAK1 Inhibitors in a Disease Model of Lupus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sareum"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Hebrew University of Jerusalem","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galmed Pharmaceuticals Announces Acceleration of its New Clinical Amilo-5MER program","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Galmed Pharmaceuticals"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"VBL Therapeutics"},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Commonwealth of Pennsylvania\u2019s COVID-19 Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melior Pharmaceuticals Awarded Grant for Advancing Pulmonary Therapeutic in COVID-19 Phase 2 Clinical Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Melior Pharmaceuticals"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artax Biopharma Announces Issuance of U.S. Composition of Matter Patent for Autoimmune Disease Program AX-158","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Artax Biopharma"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI Awarded European Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"CEL-SCI"},{"orgOrder":0,"company":"Creative Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz\u00ae Immunotherapy Product in Rheumatoid Arthritis Model","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Creative Medical"},{"orgOrder":0,"company":"IGAN Biosciences","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selecta Biosciences and IGAN Biosciences Collaborate to Study ImmTOR\u2122 Immune Tolerance Platform in Combination with IgA Protease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"IGAN Biosciences"},{"orgOrder":0,"company":"Nanoform","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoform Initiates GMP Campaign for First-in-Human Trial of Nanoformed Drug by year End","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"FINLAND","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nanoform"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Secures New European Patent for IMP761","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Pandion Therapeutics"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics Selected to Present Virtual Poster at ACR Convergence 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Ashvattha Therapeutics"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Presents OSE-230 as a Novel Agonist Monoclonal Antibody Therapy Triggering Resolution of Chronic Inflammation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Reports Positive Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Hoth Therapeutics"},{"orgOrder":0,"company":"ISD Immunotech","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ISD Immunotech, a Novo Seeds Portfolio Company, Enters Strategic Research Collaboration for the Development of a Novel Lupus Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Peptide","graph2":"ISD Immunotech"},{"orgOrder":0,"company":"BioInvent","sponsor":"Cantargia AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioInvent and Cantargia Sign Manufacturing Agreement for Monoclonal Antibody CAN10","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"BioInvent"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endocannabinoid Pathway Targeted Drug Demonstrates Proof-of-Concept Efficacy in a Cutaneous Lupus Erythematosus Mouse Model","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Hoth Therapeutics"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"HONG KONG","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Hutchison China MediTech"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"Undisclosed","newsHeadline":"EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Evoq Therapeutics"},{"orgOrder":0,"company":"Standigm","sponsor":"SK Chemicals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Standigm and SK Chemicals Repurpose FDA-Approved Drug into Rheumatoid Arthritis Candidate","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Undisclosed","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Standigm"},{"orgOrder":0,"company":"Sareum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Patent Formally Granted for Sareum\u2019s SDC-1802 TYK2\/JAK1 Inhibitor","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sareum"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noveome Biotherapeutics Publishes Preclinical Results Showing Neuroprotective Properties of ST266 Require Full Complement of Proteins","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Noveome Biotherapeutics"},{"orgOrder":0,"company":"Slate Bio","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Slate Bio Launches with Seed Financing to Develop Next Generation IL-2 Therapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Slate Bio"},{"orgOrder":0,"company":"The Wistar Institute","sponsor":"Jubilant Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jubilant Therapeutics Announces Research Collaboration with The Wistar Institute to Evaluate the Activity of Novel PAD4 Inhibitors to Reduce Clinical Severity of COVID-19","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"The Wistar Institute"},{"orgOrder":0,"company":"Imcyse","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$180.0 million","upfrontCash":"Undisclosed","newsHeadline":"Imcyse Enters into Research Collaboration and License Agreement for its Imotope\u2122 Technology with Pfizer in Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Peptide","productStatus":"Undisclosed","date":"February 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Imcyse"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pandion Therapeutics Presents Preclinical Data on Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Pandion Therapeutics"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fujifilm and Sana Biotechnology Enter Cell Therapy Partnership","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Fujifilm holding"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"Pandion Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"KBI Biopharma"},{"orgOrder":0,"company":"Rodeo Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$721.0 million","upfrontCash":"$55.0 million","newsHeadline":"Amgen to Acquire Rodeo Therapeutics Corporation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Rodeo Therapeutics"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hansa Biopharma Enters Preclinical Research Collaboration with Argenx","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Hansa Biopharma"},{"orgOrder":0,"company":"ImmunOs Therapeutics","sponsor":"Eurostars","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmunOs Therapeutics Receives Public Funding from Eurostars and Innosuisse for a Novel Antibody to Treat Inflammatory Rheumatic Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"ImmunOs Therapeutics"},{"orgOrder":0,"company":"MetrioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long-term Toxicology Studies Confirm Very Good Safety Profile of MP1032","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"MetrioPharm"},{"orgOrder":0,"company":"Yale University","sponsor":"Aptorum","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Yale University"},{"orgOrder":0,"company":"Interline Therapeutics","sponsor":"Foresite Capital","pharmaFlowCategory":"D","amount":"$92.0 million","upfrontCash":"Undisclosed","newsHeadline":"Interline Therapeutics Launches With $92 Million to Map and Correct Dysfunctional Protein Communities","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Interline Therapeutics"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Autobahn Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Autobahn Therapeutics Acquires Clinical-Stage FAAH Inhibitor from Astellas, Strengthening its Brain Targeting Chemistry Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Astellas Pharma"},{"orgOrder":0,"company":"Equillium","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Study Itolizumab in Rheumatic Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Equillium"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Alpine Immune Sciences"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"aTyr Pharma"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apollo Therapeutics Completes $145 Million Financing Led by Patient Square Capital to Expand and Advance Portfolio-Based Drug Development","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Apollo Therapeutics"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"Abata Therapeutics Launches to Usher in New Era of Cell Therapy Using Targeted Regulatory T Cells","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Abata Therapeutics"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$312.0 million","upfrontCash":"$12.0 million","newsHeadline":"F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"F-star Therapeutics"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artax Biopharma Granted MHRA Clinical Trial Authorization for AX-158","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Artax Biopharma"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences to Host Research and Development Day on CB 4332 and Complement Programs","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Catalyst Biosciences"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"GentiBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GentiBio, Forge Biologics Ink Development and Manufacturing Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Forge Biologics"},{"orgOrder":0,"company":"Nutrapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nutra Pharma Files Updated Provisional Patent for Nerve Agent Counter Measures","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Nutrapharma"},{"orgOrder":0,"company":"Cyrus Biotechnology","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Cyrus Biotechnology"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","amount":"$91.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alpine Immune Sciences Announces $91 Million Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Alpine Immune Sciences"},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AFYX Therapeutics Presents New Study Showing Therapeutic Antibody Delivery to Oral Mucosa Using Rivelin Biodegradable Mucoadhesive Patch","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"AFYX Therapeutics"},{"orgOrder":0,"company":"Medsenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medsenic Receives Notice of Approval for a New US Patent Broadening the Use of Arsenic Trioxide to Treat the Relapsing-Remitting Form of Multiple Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Medsenic"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Viva BioInnovator","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IpiNovyx Bio Closes $10 Million Seed Financing to Advance Best-in-Class Immunoproteasome Inhibitors Toward First-in-Human Clinical Studies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Orange Grove Bio"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Evelo Biosciences"},{"orgOrder":0,"company":"Genovis","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selecta Biosciences and Genovis Enter Exclusive License Agreement to Advance Next-Generation IgG Protease in Gene Therapy and Autoimmune Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Genovis"},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome at ESGCT 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cellectis"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inmagene Files Two International Patent Applications","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Inmagene Biopharmaceuticals"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventus Therapeutics to Present Data for Novel Brain-Penetrant NLRP3 Small Molecule Inhibitors for the Treatment of Inflammatory and Neurological Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Ventus Therapeutics"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"$1,560.0 million","upfrontCash":"$25.0 million","newsHeadline":"Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Alpine Immune Sciences"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Immutep","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immutep Advances IMP761 Manufacturing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"LITHUANIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Northway Biotechpharma"},{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Chord Therapeutics"},{"orgOrder":0,"company":"Amagma Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amagma Therapeutics Announces Strategic Partnership with Innovent Biologics in Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Amagma Therapeutics"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$88.0 million","upfrontCash":"$8.0 million","newsHeadline":"Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA\u00ae (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Xbrane Biopharma"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"SoftBank Vision Fund 2","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ventus Therapeutics Closes $140 Million Series C Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Ventus Therapeutics"},{"orgOrder":0,"company":"Alvotech","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech and Fuji Pharma Expand Partnership for Additional Biosimilar Candidate in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Alvotech"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Cincinnati Children\u2019s Hospital Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cincinnati Children\u2019s Hospital Medical Center and Orange Grove Bio Establish Collaboration to Develop and Commercialize Novel Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Orange Grove Bio"},{"orgOrder":0,"company":"MiroBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MiroBio Continues Expansion of Executive Leadership Team with Key Appointments to Advance Development of Checkpoint Agonist Antibodies for Autoimmune Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"MiroBio"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"VYNE Therapeutics"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAge Developing a Novel Class of Potent NLRP3 Inhibitors With Distinct Structural and Pharmacologic Properties for Inflammatory and Age-Related Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"BioAge Labs"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Kymera Therapeutics"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2022 American Transplant Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Enosi Therapeutics","sponsor":"Danuo Science Group","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"$5.0 million","newsHeadline":"Enosi Therapeutics Partners with Danuo Science Group to Accelerate Multiple Therapeutic Programs","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Enosi Therapeutics"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"},{"orgOrder":0,"company":"Aditxt","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI\u2122-100 Advancing it Closer to First-in-Human Trials","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Aditxt"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation Checkpoint","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"BERMUDA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Altamira Therapeutics"},{"orgOrder":0,"company":"Curia","sponsor":"Replicate Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Curia"},{"orgOrder":0,"company":"Trethera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Trethera"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Oral Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) at the International Congress of The Transplantation Society (TTS 2022)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma to Present at Two September 2022 Scientific Conferences","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Cue Biopharma"},{"orgOrder":0,"company":"Aditxt","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aditxt Announces Pricing of $20.0 Million Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Aditxt"},{"orgOrder":0,"company":"Lactiga","sponsor":"1517 Fund","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Lactiga Therapeutics Raises $1.6M USD in Oversubscribed Pre-Seed Round, Secures $350k in Research Grants","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Lactiga"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Rejection in Allograft and Xenograft Transplantation in Animal Models at the International Congress of The Transplantation Society (TT","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Immunovant"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Hanall Biopharma"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Cabaletta Bio","pharmaFlowCategory":"D","amount":"$162.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cabaletta Bio and IASO Biotherapeutics Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"IASO Bio"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Biora Therapeutics"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia's CAN10 Demonstrates Positive Activity In Systemic Sclerosis Models In New Data Presented At ACR Convergence 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Cantargia AB"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Pharmaceuticals Granted Orphan Drug Designation for CAN 106 for the Treatment of Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Ribon Therapeutics"},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Allakos"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Boston Children's Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Collaboration with Boston Children\u2019s Hospital to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in Animals","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Neoleukin Therapeutics"},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Rallybio"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"University of Maryland","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Silo Pharma"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$658.5 million","upfrontCash":"Undisclosed","newsHeadline":"Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Evoq Therapeutics"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ventus Therapeutics Nominates Potential First-in-Class cGAS Inhibitor VENT-03 as Inaugural Development Candidate in cGAS Franchise","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Ventus Therapeutics"},{"orgOrder":0,"company":"eGenesis","sponsor":"Eledon Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"eGenesis"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Jasper Therapeutics"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"Undisclosed","newsHeadline":"EVOQ Therapeutics and Amgen Expanding Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Evoq Therapeutics"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Foundation for Biomedical Research and Innovation at Kobe","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Novel Anti-PD-1 Agonist Antibody with Immunosuppressive Effect Discovered Through Joint Research Between Meiji Seika Pharma and The Foundation for Biomedical Research and Innovation at Kobe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Meiji Seika Pharma"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"University of Maryland","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Research Agreement with University of Maryland, Baltimore, to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Heart Xenograft Transplantation in Animals","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"IgGenix","sponsor":"Alexandria Venture","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"IgGenix"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Biora Therapeutics"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$220.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Cue Biopharma"},{"orgOrder":0,"company":"Thymmune Therapeutics","sponsor":"Pillar VC","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Thymmune Therapeutics"},{"orgOrder":0,"company":"IgGenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IgGenix Announces Patent Granted by USPTO Covering the Generation of Allergen-specific Antibodies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"IgGenix"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jubilant Therapeutics Inc.'s Selective, Orally Administered PAD4 Inhibitor Demonstrates Activity in Rheumatoid Arthritis Preclinical Models","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Jubilant Therapeutics"},{"orgOrder":0,"company":"Ossium Health","sponsor":"California Institute of Regenerative Medicine","pharmaFlowCategory":"D","amount":"$3.4 million","upfrontCash":"Undisclosed","newsHeadline":"Ossium Health Awarded $3.46M in Funding From The California Institute of Regenerative Medicine (CIRM) to Advance the Development of OSSM-007 for the Treatment of Steroid-Refractory Acute Graft versus Host Disease (GVHD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Ossium Health"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"TD Cowen","pharmaFlowCategory":"D","amount":"$87.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cabaletta Bio Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cabaletta Bio"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"TD Cowen","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cabaletta Bio"},{"orgOrder":0,"company":"Alvotech","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$343.4 million","upfrontCash":"$60.1 million","newsHeadline":"Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Five Proposed Biosimilars in Europe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Alvotech"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Monte Rosa Therapeutics"},{"orgOrder":0,"company":"Exo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exo Announces Lead Program, Targeting TANK Binding Kinase 1 (TBK1), for the Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Exo Therapeutics"},{"orgOrder":0,"company":"Immutep","sponsor":"Charles River Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immutep Selects Charles River Laboratories for IMP761\u2019s GLP Toxicology Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Immutep"},{"orgOrder":0,"company":"Celltrion","sponsor":"Rani Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Celltrion"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Walloon Region","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hyloris has been Granted EUR 1 Million in Non-Dilutive Funding from the Walloon Region","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Hyloris Pharmaceuticals"},{"orgOrder":0,"company":"Recludix Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,325.0 million","upfrontCash":"Undisclosed","newsHeadline":"Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Recludix Pharma"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Alger","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Forte Biosciences"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Trethera Receives NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Trethera"},{"orgOrder":0,"company":"Mysthera Therapeutics","sponsor":"Forty51 Ventures","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Mysthera Therapeutics"},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Cabaletta Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"WuXi Advanced Therapies"},{"orgOrder":0,"company":"BITT","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BITT Announces NIH Award for Advancement of Anti-CD40 Antibody","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"BITT"},{"orgOrder":0,"company":"IMIDomics","sponsor":"TNAX Biopharma Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IMIDomics Inc. Secures Exclusive Worldwide Licensing Agreement with TNAX Biopharma Corporation for TNAX101A (IMB1001), A Promising Drug Candidate for Immune-Mediated Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"IMIDomics"},{"orgOrder":0,"company":"Evommune","sponsor":"Maruho","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evommune Announces Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 Antagonist EVO756 in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Evommune"},{"orgOrder":0,"company":"Thymmune Therapeutics","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"Undisclosed","newsHeadline":"Thymmune Therapeutics Receives $37M in Funding from the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Thymmune Therapeutics"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"IMIDomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IMIDomics Announces Strategic Agreement with WuXi Biologics to Advance IMB1001 Antibody Development for Immune-Mediated Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"WuXi Biologics"},{"orgOrder":0,"company":"IMIDomics","sponsor":"University of Barcelona","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IMIDomics Establishes a License and Collaboration Partnership with the University of Barcelona to Advance Treatments for IMIDs","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"IMIDomics"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Ingenia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences and INGENIA Therapeutics Enter into Collaboration Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Nona Biosciences"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Rani Therapeutics"},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","amount":"$101.0 million","upfrontCash":"Undisclosed","newsHeadline":"Odyssey Therapeutics Announces $101 Million Series C Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Odyssey Therapeutics"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"BTIG, LLC","pharmaFlowCategory":"D","amount":"$26.5 million","upfrontCash":"Undisclosed","newsHeadline":"Coya Therapeutics Announces Closing of $26.5 Million Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Coya Therapeutics"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","amount":"$315.5 million","upfrontCash":"$7.5 million","newsHeadline":"TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision's Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Precision BioSciences"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xeris Biopharma Enters into an Exclusive Worldwide License Agreement for Xeriject\u00ae Formulation of Teprotumumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Xeris Pharmaceuticals"},{"orgOrder":0,"company":"Phebra","sponsor":"BioSenic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioSenic Reaches Agreement on a Binding Term Sheet with Phebra PTY Ltd. with Respect to the Development of the First Oral Formulation of Arsenic Troxide for cGvHD Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Phebra"},{"orgOrder":0,"company":"Synthekine","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$40.0 million","newsHeadline":"Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Synthekine"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","amount":"$305.5 million","upfrontCash":"$17.5 million","newsHeadline":"Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Precision BioSciences"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$713.0 million","upfrontCash":"$48.0 million","newsHeadline":"AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Capstan Therapeutics Announces $175M Oversubscribed Series B Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Capstan Therapeutics"},{"orgOrder":0,"company":"IMIDomics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UCB announces Strategic Investment in IMIDomics, Inc to Advance Breakthrough Solutions for Immune-Mediated Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"IMIDomics"},{"orgOrder":0,"company":"BioSenic","sponsor":"Gestys Sant\u00e9 Biotech","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"BioSenic Raises \u20ac500,000 in Private Placement of New Shares with Established New Investors","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"BioSenic"},{"orgOrder":0,"company":"UNeMed","sponsor":"Coya Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"UNeMed"},{"orgOrder":0,"company":"IFM Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$835.0 million","upfrontCash":"$90.0 million","newsHeadline":"Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"IFM Therapeutics"},{"orgOrder":0,"company":"IgGenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IgGenix Presents Groundbreaking Research Using its SEQ SIFTER Antibody Discovery Platform for Lead Program in Peanut Allergy at the 2024 AAAAI Annual Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"IgGenix"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$1,903.5 million","upfrontCash":"$45.0 million","newsHeadline":"Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Nurix Therapeutics"}]

Find Novel Immunology Drugs in Preclinical Development

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            The collaboration aims to support the clinical development of GS-6791 (NX-0479), a potent, selective, oral IRAK4 degrader that has potential applications in the treatment of rheumatoid arthritis and other inflammatory diseases

            Lead Product(s): NX-0479

            Therapeutic Area: Immunology Product Name: GS-6791

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Gilead Sciences

            Deal Size: $1,903.5 million Upfront Cash: $45.0 million

            Deal Type: Collaboration April 02, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The proceeds will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline.

            Lead Product(s): CPTX2309

            Therapeutic Area: Immunology Product Name: CPTX2309

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: RA Capital Management

            Deal Size: $175.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing March 20, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The acquisition provides Novartis with full rights to IFM Due's portfolio of STING antagonists, which have the potential to treat an array of serious inflammation-driven diseases characterized by excessive interferon and other pro-inflammatory cytokine signaling.

            Lead Product(s): Undisclosed

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

            Deal Size: $835.0 million Upfront Cash: $90.0 million

            Deal Type: Acquisition March 13, 2024